参考文献

［1］ALIFRANGIS C，MCGOVERN U，FREEMAN A，et al.Molecular and histopathology directed therapy for advanced bladder cancer［J］.Nat Rev Urol，2019，16（8）：465-483.

［2］GROSSMAN H B，NATALE R B，TANGEN C M，et al.Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer［J］.N Engl J Med，2003，349（9）：859-866.

［3］GRIFFITHS G，HALL R，SYLVESTER R，et al.International phase III trial assessing neoadjuvant cisplatin，methotrexate，and vinblastine chemotherapy for muscle-invasive bladder cancer：long-term results of the BA06 30894 trial［J］.J Clin Oncol，2011，29（16）：2171-2177.

［4］FELSENSTEIN K M，THEODORESCU D.Precision medicine for urothelial bladder cancer：update on tumour genomics and immunotherapy［J］.Nature Reviews Urology，2018，15（2）：92-111.

［5］TRIPATHI A，GRIVAS P.The utility of next generation sequencing in advanced urothelial carcinoma［J］.European Urology Focus，2020，6（1）：41-44.

［6］GIRIDHAR K V，KOHLI M.Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer［J］.Mayo Clinic Proceedings，2017，92（10）：1564-1582.

［7］Cancer Genome Atlas Research Network.Comprehensive molecular characterization of urothelial bladder carcinoma［J］.Nature，2014，507（7492）：p.315-322.

［8］ROBERTSON A G，KIM J，AL-AHMADIE H，et al.Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer［J］.Cell，2017，171（3）：540-556.

［9］DAMRAUER J S，HOADLEY K A，CHISM D D，et al.Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology［J］.Proceedings of the National Academy of Sciences，2014，111（8）：3110-3115.

［10］SJODAHL G，LAUSS M，LOVGREN K，et al.A Molecular Taxonomy for Urothelial Carcinoma［J］.Clinical Cancer Research，2012，18（12）：3377-3386.

［11］CHOI W，PORTEN S，KIM S，et al.Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy［J］.Cancer Cell，2014，25（2）：152-165.

［12］AINE M，ERIKSSON P，LIEDBERG F，et al.Biological determinants of bladder cancer gene expression subtypes［J］.Sci Rep，2015，5：10957.

［13］JUNG M，KIM B，MOON K C.Immunohistochemistry of cytokeratin（CK）5/6，CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma［J］.Histopathology，2019，74（3）：483-493.

［14］DADHANIA V，ZHANG M，ZHANG L，et al.Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use［J］.EBioMedicine，2016，12：105-117. a01F5aZ0ewSwJhwzx85LI94nNkY5LgoPKm/gYDVK1pYEZjTz0XmSuwoKC3iNFGb0